Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS - Free Report) in a report released on Monday. The firm issued a sell rating on the stock.

Separately, HC Wainwright restated a "buy" rating and issued a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Stock Performance

Shares of SENS stock remained flat at $0.31 during trading hours on Monday. The stock had a trading volume of 3,737,642 shares, compared to its average volume of 2,958,796. The company's fifty day simple moving average is $0.33 and its two-hundred day simple moving average is $0.38. The stock has a market capitalization of $184.61 million, a P/E ratio of -2.40 and a beta of 0.79. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a fifty-two week low of $0.28 and a fifty-two week high of $0.75.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company's stock worth $11,963,000 after buying an additional 155,715 shares during the period. Geode Capital Management LLC raised its stake in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock valued at $2,042,000 after acquiring an additional 179,103 shares in the last quarter. Symmetry Partners LLC acquired a new position in Senseonics during the 3rd quarter worth $164,000. Cubist Systematic Strategies LLC grew its stake in shares of Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company's stock valued at $196,000 after purchasing an additional 51,000 shares during the period. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.